Table 2 GRADE evidence profile: TXA for bleeding patients
Certainty assessment | No. of patients | Effect | Certainty | Importance | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | TXA | Control | Relative (95% CI) | Absolute (95% CI) | ||
Thrombotic events | ||||||||||||
230 | Randomized trials | Not serious | Not serious | Not serious | Not serious | None | 1342/52103 (2.5%) | 1278/50211 (2.5%) | RR 1.00 (0.93 to 1.08) | 0 fewer per 1000 (from 2 fewer to 2 more) | ⨁⨁⨁⨁ HIGH | CRITICAL |
Seizures | ||||||||||||
40 | Randomized trials | Not serious | Not seriousb | Not serious | Seriousa | None | 404/30351 (1.3%) | 351/29847 (1.1%) | RR 1.18 (0.91 to 1.53) | 2 more per 1000 (from 1 fewer to 6 more) | ⨁⨁⨁◯ MODERATE | CRITICAL |
Seizures (dose > 2 g/day) | ||||||||||||
7 | Randomized trials | Not serious | Not serious | Not serious | Not serious | None | 55/8642 (0.6%) | 24/8666 (0.3%) | RR 3.05 (1.01 to 9.20) | 6 more per 1000 (from 0 fewer to 23 more) | ⨁⨁⨁⨁ HIGH | CRITICAL |
Seizures (dose ≤ 2 g/day) | ||||||||||||
33 | Randomized trials | Not serious | Not serious | Not serious | Not serious | None | 349/21709 (1.6%) | 327/21181 (1.5%) | RR 1.02 (0.88 to 1.19) | 0 more per 1000 (from 2 fewer to 3 more) | ⨁⨁⨁⨁ HIGH | CRITICAL |